Trial to Evaluate Efficacy of Magnetic Resonant Therapy (MRT) in PTSD

- Willing and able to adhere to the treatment schedule and all required study visits.

- Any non-Active Duty Military are included.

- PCL-M > 45

- Primary diagnosis of Posttraumatic Stress Disorder rendered by the Clinician Administered PTSD Scale (CAPS)

- Individuals diagnosed by the Investigator with the following conditions (current unless otherwise stated): History of open skull traumatic brain injury. History of clinically significant seizure disorder.

- Individuals with a clinically defined neurological disorder including, but not limited to: Any condition likely to be associated with increased intracranial pressure. Space occupying brain lesion. History of cerebrovascular accident. Cerebral aneurysm.

- EEG abnormalities that indicate risk of seizure, i.e., abnormal focal or general slowing or spikes during the EEG recording.

- Any type of rTMS treatment within 3 months prior to the screening visit.

- Currently under antipsychotic medication treatment.

- Intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, stents, or electrodes) or any other metal object within or near the head, excluding the mouth, which cannot be safely removed.

- Clinically significant abnormality or clinically significant unstable medical condition that in the Investigator's judgment might pose a potential safety risk to the subject or limit interpretation of the trial results.

- Clinically significant medical illness, including any uncontrolled thyroid disorders, hepatic, cardiac, pulmonary and renal malfunctioning.

- Any condition which in the judgment of the investigator would prevent the subject from completion of the study.

- Inability to acquire a clinically satisfactory EEG/ECG on a routine basis.

- Grossly abnormal electrolyte or cell blood count panels suggestive of other pathology at study initiation.

- Active Duty Military are excluded.